Entrada Therapeutics (TRDA)
(Delayed Data from NSDQ)
$14.72 USD
-0.31 (-2.06%)
Updated Sep 10, 2024 04:00 PM ET
After-Market: $14.70 -0.02 (-0.14%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth A Momentum C VGM
Brokerage Reports
0 items in cart
Entrada Therapeutics, Inc. [TRDA]
Reports for Purchase
Showing records 1 - 13 ( 13 total )
Company: Entrada Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
ENTR-601-44 Positive Phase 1 Data; Equity Financing; Lowering PT to $18
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Entrada Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
1Q24 Financial Results Reported; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Entrada Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Gene Juice: RNA Editing Rises to the Forefront of RNA Therapeutics
Provider: H.C. Wainwright & Co., Inc.
Analyst: KAPOOR M
Company: Entrada Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Runway Extended Through 2Q26; 2023 Financials; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Entrada Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
ENTR-601-44 FDA Clinical Hold Maintained; Lowering PT to $20
Provider: H.C. Wainwright & Co., Inc.
Analyst: PACHAIYAPPAN B
Company: Entrada Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Optimized Entry and Exit Levels for TRDA 112223
Provider: Stock Traders Daily
Analyst: Research Department
Company: Entrada Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Clinical Pipeline Progress; 3Q23 Financial Results; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PACHAIYAPPAN B
Company: Entrada Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Dosing Starts in ENTR-601-44 Trial in Healthy Volunteers; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PACHAIYAPPAN B
Company: Entrada Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
ENTR-601-44 Phase 1 Trial Starting Next Month; 2Q23 Financials; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PACHAIYAPPAN B
Company: Entrada Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
ENTR-601-44 Receives U.K. Clinical Entry Authorization; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PACHAIYAPPAN B
Company: Entrada Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Clinical Hold Lift Still Possible Near-Term; 1Q23 Financials; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Company: Entrada Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Competitor Exon-44 Agent Receives Fast Track Designation; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Company: Entrada Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Disrupting Complex Intracellular Drug Delivery; Initiating at Buy and $25 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
|